Beam Therapeutics Management
Management criteria checks 4/4
Beam Therapeutics' CEO is John Evans, appointed in Apr 2017, has a tenure of 7.58 years. total yearly compensation is $6.28M, comprised of 10.9% salary and 89.1% bonuses, including company stock and options. directly owns 1.11% of the company’s shares, worth $20.10M. The average tenure of the management team and the board of directors is 5.2 years and 4.5 years respectively.
Key information
John Evans
Chief executive officer
US$6.3m
Total compensation
| CEO salary percentage | 10.9% |
| CEO tenure | 7.6yrs |
| CEO ownership | 1.1% |
| Management average tenure | 5.2yrs |
| Board average tenure | 4.5yrs |
Recent management updates
Recent updates
Insufficient Growth At Beam Therapeutics Inc. (NASDAQ:BEAM) Hampers Share Price
Oct 28
Beam Therapeutics: Still Holding Fast To Generous Valuation, Still Not A Buy
Sep 29We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn
Sep 04Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares
Jul 12Beam Therapeutics: Slow Developmental Progress, But Promising Potential
Jul 01We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn
May 13Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects
Apr 24Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S
Apr 07Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 01Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade
Feb 29Beam Therapeutics: Cool Tech, But At A Way Inflated Price For Now
Feb 08This Just In: Analysts Are Boosting Their Beam Therapeutics Inc. (NASDAQ:BEAM) Outlook for This Year
Nov 01We're Hopeful That Beam Therapeutics (NASDAQ:BEAM) Will Use Its Cash Wisely
Jul 23Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation
Apr 08Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts
Nov 08Beam Therapeutics: Now Is Not The Right Time To Own
Sep 15Beam Therapeutics GAAP EPS of -$1.02 misses by $0.05, revenue of $16.65M beats by $7.21M
Aug 09Beam drops 19% as FDA issues clinical hold on blood cancer candidate
Aug 01Revisiting Beam Therapeutics Among Collaborative Catalysts
Jul 10Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts
May 10Beam Therapeutics Worth Watching Because Of Pfizer Interest?
Apr 21Beam Therapeutics: Getting More And More Interesting
Apr 10Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 03Some Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 02Pfizer's Partnership With Beam Therapeutics About Becoming Global Leader In mRNA/Gene Therapy
Jan 19Beam Therapeutics: An Early Company In A Promising Field
Dec 27Beam Therapeutics: Recent Selling Pressure Leaves Behind A CRISPR Buying Opportunity
Dec 20Beam Therapeutics: This Technology Should Be Part Of Every Investor's Portfolio
Oct 01CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$143m |
| Mar 31 2024 | n/a | n/a | -US$135m |
| Dec 31 2023 | US$6m | US$685k | -US$133m |
| Sep 30 2023 | n/a | n/a | -US$285m |
| Jun 30 2023 | n/a | n/a | -US$327m |
| Mar 31 2023 | n/a | n/a | -US$316m |
| Dec 31 2022 | US$9m | US$650k | -US$289m |
| Sep 30 2022 | n/a | n/a | -US$315m |
| Jun 30 2022 | n/a | n/a | -US$234m |
| Mar 31 2022 | n/a | n/a | -US$238m |
| Dec 31 2021 | US$14m | US$590k | -US$371m |
| Sep 30 2021 | n/a | n/a | -US$401m |
| Jun 30 2021 | n/a | n/a | -US$408m |
| Mar 31 2021 | n/a | n/a | -US$366m |
| Dec 31 2020 | US$907k | US$529k | -US$196m |
| Sep 30 2020 | n/a | n/a | -US$132m |
| Jun 30 2020 | n/a | n/a | -US$119m |
| Mar 31 2020 | n/a | n/a | -US$106m |
| Dec 31 2019 | US$2m | US$473k | -US$91m |
| Sep 30 2019 | n/a | n/a | -US$86m |
| Jun 30 2019 | n/a | n/a | -US$134m |
| Mar 31 2019 | n/a | n/a | -US$124m |
| Dec 31 2018 | US$4m | US$441k | -US$117m |
Compensation vs Market: John's total compensation ($USD6.28M) is about average for companies of similar size in the US market ($USD5.64M).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
CEO
John Evans (46 yo)
7.6yrs
Tenure
US$6,280,099
Compensation
Mr. John M. Evans, M.B.A., is CEO & Director of Beam Therapeutics Inc. from January 2020. He joined the Beam Therapeutics Inc. in 2017. He was President, CEO & Director of Beam Therapeutics Inc. until Janu...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 7.6yrs | US$6.28m | 1.11% $ 20.1m | |
| President | 4.8yrs | US$2.79m | 0.12% $ 2.2m | |
| Senior VP | 5.6yrs | US$2.28m | 0.055% $ 994.7k | |
| Chief Medical Officer | 3.7yrs | US$2.55m | 0.0017% $ 31.4k | |
| Co-Founder | no data | no data | no data | |
| Co-Founder | no data | no data | no data | |
| Co-Founder | no data | no data | no data | |
| Senior VP of Finance & Treasurer | no data | no data | 0.0083% $ 150.3k | |
| Chief Technology Officer | no data | no data | no data | |
| Chief Scientific Officer | 1.7yrs | no data | no data | |
| Chief Human Resources Officer | 7.3yrs | no data | no data | |
| Chief Manufacturing Officer | no data | no data | no data |
5.2yrs
Average Tenure
56.5yo
Average Age
Experienced Management: BEAM's management team is seasoned and experienced (5.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | no data | US$6.28m | 1.11% $ 20.1m | |
| Independent Director | 3yrs | US$435.22k | 0% $ 0 | |
| Independent Lead Director | 6.5yrs | US$465.22k | 0.022% $ 389.9k | |
| Independent Director | 5.1yrs | US$450.22k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$447.72k | 0% $ 0 | |
| Independent Director | less than a year | US$772.68k | no data | |
| Independent Director | 6yrs | US$442.72k | 0% $ 0 |
4.5yrs
Average Tenure
57yo
Average Age
Experienced Board: BEAM's board of directors are considered experienced (4.5 years average tenure).